Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic Cancers

Eur Urol Focus. 2022 May;8(3):639-640. doi: 10.1016/j.euf.2022.04.011. Epub 2022 May 7.


There are currently few situations in which genomic testing is actionable for genitourinary tumors. Without clear indications or treatment paradigms, genomic sequencing cannot be recommended as a standard of care for genitourinary tumors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Genomics
  • Humans
  • Standard of Care
  • Urogenital Neoplasms* / diagnosis
  • Urogenital Neoplasms* / genetics
  • Urogenital Neoplasms* / therapy
  • Urologic Neoplasms* / diagnosis
  • Urologic Neoplasms* / genetics
  • Urologic Neoplasms* / therapy